Rare cancers are characterized by the National Institute of Health as those malignancies which inflect less than 40,000 people annually in the United States. Combined, all rare cancers account for about 25% of all cancer diagnoses. Unfortunately, research and development of new therapies for rare cancers is challenging, resulting in slow progress for new therapeutic approaches. While rare cancers exist in many organs throughout the body, all childhood cancers are considered rare.
-
Theragen Bio. (TheragenEtex Subsidiary company) has been conducted the genome-wide research and the genome-based genetic testing services. From 2007, researchers of Theragen Bio. are collabo...
Most bladder cancer (BC) cases are non-muscle-invasive BC (NIBMC), which is rarely lethal. However, nearly one-fifth of NMIBC cases progress to muscle-invasive BC (MIBC), which shows a 5-yea...
DATE: June 26, 2020 TIME: 8:00am PT Structural variants (SVs) are an important source of genetic variation in the human genome and they are involved in a multitude of human diseases as well...
DATE: June 18, 2020 TIME: 9:00am PDT, 12:00pm EDT Despite the success of immunotherapy against several malignancies including melanoma and lung adenocarcinoma, glioblastoma remains the excep...
The mammary gland is a unique organ that develops predominantly after birth and undergoes dramatic remodelling in reproductive phases. Macrophages have been implicated in mammary gland funct...
Precision medicine is the paradigm to develop treatments for patients based on molecular-targets that are effective in vivo when administered. In addition to identifying the molecular and ce...
The International Council for Standardization in Haematology (ICSH) is a nonprofit organization dedicated to providing open-access guidance documents to enhance the quality of laboratory tes...